Karen S Stevens

US Patent:

20160000926, Jan 7, 2016

Filed:

Feb 27, 2015

Appl. No.:

14/634575

Inventors:

- Denver CO, US
Raymond BUNCH - Phoenix AZ, US
Tom ANCHORDOQUY - Lakewood CO, US
Karen E. STEVENS - Westminster CO, US

Assignee:

The Regents of the University of Colorado, a body corporate - Denver CO

International Classification:

A61K 47/40
A61K 31/325
A61K 31/7076
A61K 31/53
A61K 9/00
A61K 31/19
A61K 31/55
A61K 31/15
A61K 31/138
A61K 31/135
A61K 31/5513
A61K 31/196

Abstract:

The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.

US Patent:

20140100183, Apr 10, 2014

Filed:

Apr 12, 2013

Appl. No.:

13/862225

Inventors:

- Denver CO, US
Raymond BUNCH - Phoenix AZ, US
Tom ANCHORDOQUY - Lakewood CO, US
Karen E. STEVENS - Westminster CO, US

Assignee:

The Regents of the University of Colorado, a body corporate - Denver CO

International Classification:

A61K 9/00
A61K 31/53
A61K 31/135
A61K 31/196
A61K 31/5513
A61K 31/19
A61K 31/4178
A61K 31/519
A61K 31/138
A61K 31/7076
A61K 31/42
A61K 47/40
A61K 31/55
A61K 47/26
A61K 31/15
A61K 31/27

US Classification:

514 46, 514483, 514242, 514656, 514562, 514220, 514557, 514397, 51425941, 514651, 514378, 514217, 514654, 514647

Abstract:

The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.